Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyCRDF +8.68%31 Debt-to-Equity is 0.02 as of Mar. 2026, which is 33% below its 10-year median of 0.03. GuruFocus rates CRDF with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 968 Biotechnology companies, Cardiff Oncology ranks better than 87.81% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cardiff Oncology's Debt-to-Equity or its related term are showing as below:
CRDF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 1.55
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Cardiff Oncology was 1.55. The lowest was 0.00. And the median was 0.03.
CRDF's Debt-to-Equity is ranked better than 87.81% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs CRDF: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cardiff Oncology Debt-to-Equity Related Terms
Cardiff Oncology Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRDF vs MNOV, PMVP, CING: Debt-to-Equity Comparison
For the Biotechnology subindustry, Cardiff Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cardiff Oncology and its competitors. This is 33% below median its historical median of 0.03. According to the industry distribution chart, Cardiff Oncology ranks #118 out of 968 companies in the Biotechnology industry, placing it in the top 12.2%.
Is Cardiff Oncology's Debt-to-Equity too high?
Cardiff Oncology's current Debt-to-Equity of 0.02 is 33% below median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Cardiff Oncology's value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Cardiff Oncology ranks #118 out of 968 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Debt-to-Equity compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #118 out of 968 companies for Debt-to-Equity. This places Cardiff Oncology in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Cardiff Oncology's value of 0.02 is 87.5% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Cardiff Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Debt-to-Equity is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02, which is 33% below median its 10-year median of 0.03 and 87.5% below the Biotechnology industry median of 0.16. Cardiff Oncology's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score
Get the complete analysis for CRDF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
